Anti-Smoking Vaccine from Glaxo - Zibb.com

Nov 18, 2009 (Zacks.com via COMTEX) --

GlaxoSmithKline (GSK) and Nabi Biopharmaceuticals (NABI) signed a licensing agreement for a nicotine conjugate vaccine (NicVAX) as well as for the development of a second generation nicotine vaccine. NicVAX is an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse. Earlier in October, the vaccine received a $10 million grant from the National Institute on Drug Abuse. As per the agreement, Nabi will get an upfront payment of $40 million and is eligible to receive more than $500 million (together with upfront payment) as option fees and milestones for the vaccine, NicVAX, and follow-on nicotine vaccines. Nabi has the potential to receive double-digit royalties from sales if the product is commercialized. GlaxoSmithKline will have an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-generation nicotine vaccines using Nabi's intellectual property together with GSK's own technology. NicVAX is currently being studied in the first of two phase III clinical trials with results expected at the end of 2010. While Nabi will be responsible for the development of this vaccine, GlaxoSmithKline on exercising its option will take responsibility for further development and commercialization of NicVAX. Company estimates put the worldwide number of smokers at about 1.2 billion and smoking causes approximately 5.4 million deaths per year. In view of the huge increase in the number of smokers, Datamonitor expects the global market for smoking cessation to reach $4.6 billion by 2016 and vaccines could account for $2 billion in sales. Currently available smoking cessation therapies have relapse rates which can be as high as 90% in the first year after a smoker quits. Although the vaccine holds immense potential, we however remain concerned about its successful development. In October, an anti-smoking vaccine developed by Cytos Biotechnology and Novartis (NVS) missed its main goal in a mid-stage study.

Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Investment Research.See all today's Analyst Blog entries.

Tags: biopharmaceuticals   biotechnology   clinical   investment   investment opinion   market   property   rates   research   sales   smoking   technology   vaccine  

Companies: GlaxoSmithKline plc (GSK), Novartis AG (NVS)

Permalink

GlaxoSmithKline and Nabi sign option and licensing agreement - Zibb.com

Nov 18, 2009 (Datamonitor via COMTEX) --

GlaxoSmithKline Biologicals and Nabi Biopharmaceuticals have signed an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine, NicVAX, an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine.

Under the terms of the agreement, GlaxoSmithKline (GSK) will pay to Nabi an upfront non-refundable fee of $40 million at closing and will receive an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-generation nicotine vaccines using Nabi's intellectual property.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Read more...

Tags: biopharmaceuticals   exercise   president   property   sales   smoking   technology   vaccine  

Companies: GlaxoSmithKline plc (GSK)

Permalink

bioMerieux and GlaxoSmithKline sign agreement to develop test for breast cancer - Zibb.com

Nov 18, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

bioMerieux SA, a France-based developer and manufacturer of biologic diagnostic products, has signed an agreement with GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and healthcare company, to develop a predictive test. This test, based on biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings.

The development of this new test will be co-funded by both companies. GSKwill bring its experience in the field of cancer and will also facilitate access to samples from several clinical trials under the collaboration. The new test will be developed by bioMerieux's global research and development (R&D) team, including its subsidiary, bioTheranostics.

Deal Type    Partnership
Sub-Category Development
Deal Status  Announced: 2009-11-17

Partner 1 (Company) GlaxoSmithKline plc
Partner 2 (Company) bioMerieux SA
Partner 3 (Company) bioTheranostics

Read more...

Tags: breast cancer   cancer   clinical   france   healthcare   manufacturer   partnership   pharmaceuticals   products   research and development  

Companies: GlaxoSmithKline plc (GSK)

Permalink

Astex Therapeutics signs drug discovery agreement with GlaxoSmithKline - Zibb.com

Nov 17, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

Astex Therapeutics Limited, a biotechnology company, has signed an agreement with GlaxoSmithKline plc (GSK), a pharmaceutical and healthcare company, to discover, develop, and commercialize compounds directed against multiple therapeutic targets of interest to GSK. Both the partners are based in the UK.

As part of the agreement, Astex will apply its fragment chemistry platform, Pyramid(TM), to multiple targets identified by GSK, with the objective of identifying and developing new candidate drugs. The targets have been selected from multiple therapeutic areas within GSK. Astex and GSK will form joint program teams to identify candidate compounds. Astex will be primarily responsible for the initial fragment screening and lead discovery, and GSK will primarily be responsible for optimization of the identified lead compounds. GSK will be solely responsible for completing pre-clinical and clinical development of all products arising from the collaboration, and for their commercialization globally.

Deal Value (US$ Million) 500.43
Deal Type                Partnership
Sub-Category             Research and discovery,Development,Commercialization
Deal Status              Announced: 2009-11-12

Partner 1 (Company) GlaxoSmithKline plc
Partner 2 (Company) Astex Therapeutics Limited

Read more...

Tags: biotechnology   clinical   drugs   equity   healthcare   partnership   pharmaceuticals   research  

Companies: GlaxoSmithKline plc (GSK)

Permalink